ABBOTT LABORATORIES — M&A Activity 2009

Sep 28, 2009

8-K 1 a09-28334_18k.htm 8-K

*UNITED STATES*

*SECURITIES AND EXCHANGE COMMISSION*

*Washington, D.C. 20549*

*FORM 8-K*

*CURRENT REPORT*

*Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934*

*September 26, 2009* Date of Report (Date of earliest event reported)

*ABBOTT LABORATORIES*

(Exact name of registrant as specified in its charter)

Illinois	1-2189	36-0698440
(State or other jurisdiction	(Commission File Number)	(IRS Employer
of incorporation)		Identification No.)

*100 Abbott Park Road*

*Abbott Park, Illinois 60064-6400*

(Address of principal executive offices)(Zip Code)

Registrant’s telephone number, including area code: (847) 937-6100

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

SEQ.=1,FOLIO='',FILE='C:\JMS\mweinst\09-28334-1\task3731726\28334-1-ba.htm',USER='mweinst',CD='Sep 28 14:08 2009'

*Item 1.01 Entry into a Material Definitive Agreement*

On September 28, 2009, Abbott announced it entered into a definitive agreement with the Solvay Group for Abbott to acquire Solvay’s pharmaceutical (including vaccine) and diagnostics businesses. The agreement is subject to customary closing conditions and regulatory approvals. A copy of the press release announcing the agreement is attached as Exhibit 99.1.

Item 9.01 Financial Statements and Exhibits

Exhibit No.	Exhibit
99.1	Press
Release, dated September 28, 2009.

2

SEQ.=1,FOLIO='2',FILE='C:\JMS\mweinst\09-28334-1\task3731726\28334-1-ba.htm',USER='mweinst',CD='Sep 28 14:08 2009'

*SIGNATURE*

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

/s/ Thomas C. Freyman
Thomas C. Freyman
Executive
Vice President, Finance
and
Chief Financial Officer

3

SEQ.=1,FOLIO='3',FILE='C:\JMS\mweinst\09-28334-1\task3731726\28334-1-ba.htm',USER='mweinst',CD='Sep 28 14:08 2009'

*EXHIBIT INDEX*

Exhibit No.	Exhibit
99.1	Press Release, dated September 28, 2009.

4

SEQ.=1,FOLIO='4',FILE='C:\JMS\mweinst\09-28334-1\task3731726\28334-1-ba.htm',USER='mweinst',CD='Sep 28 14:08 2009'